https://www.selleckchem.com/pr....oducts/pf-04620110.h
DOAC-treated patients (mean age 67.1±15.4years, 52.2% male) had higher relative risks (RRs) and lower 30-days event-free survival as compared to patients not on OAC for all-cause mortality (RR 1.27, 95% CI 1.12-1.44; Log-Rank test p=0.01, hospitalization/re-hospitalization (RR 1.72, 95% CI 1.64-1.82; Log-Rank test p0.001) and VTE (RR 4.51, 95% CI 3.91-5.82; Log-Rank test p0.001), but not for ICH (RR 0.90, 95% CI 0.54-1.51; Log-Rank test p=0.513). In COVID-19 patients, previous DOAC therapy at time of diagnosis was not asso
Like
Comment
Share
